Skip to main content
Main navigation
About Us
Toggle submenu for About Us
Meet Our Team
From the Executive Director
Tufts CSDD History
Our Mission
Media Mentions
Research Milestones
Financial Disclosure
Research
Toggle submenu for Research
Research Overview
Single Sponsors, Working Groups & Consortia
Diagnostic & Optimization Services
Longitudinal Studies
Research Grants & Center Sponsors
Databases
Surveys
Publications
Toggle submenu for Publications
Impact Reports
White Papers
Articles
Presentations
Insider Newsletter Archive
Training & Events
Toggle submenu for Training & Events
Training & Events Overview
Postgraduate Course in Clinical Pharmacology, Drug Development & Regulation
Leadership for Drug Development Teams
Customized On-Site & Virtual Programs
Roundtables & Forums
Get Involved
Toggle submenu for Get Involved
Media Center
Center Sponsorship
Endowed Research Grants
Contribute
Friends of CSDD
Contact Us
Breadcrumb
Home
Publications
Articles
Exposed filters
Skip filters
Filter By Core Concepts
AI/ML
Biotech
Cardiovascular
CNS
COVID-19
CROs, Site Markets & Management
Decentralized Clinical Trials (DCT)
Diabetes
Global Drug Development
Improved Access to Clinical Trials
Oncology
Operating Practices, Systems & Solutions
Patient Enrollment Performance
Pediatrics
Pharmacoeconomics
Pharmacovigilance
Pipeline Trends & Characteristics
Protocol Design & Optimization
Rare Diseases
Regenerative Medicine
Regulatory
Regulatory Affairs
Authors
- Any -
Abigail Dirks
Beth Harper
Hana Do
Jennifer Kim
Joseph DiMasi
Kenneth Getz
Kenneth Kaitin
Linda Sullivan
Marc Blaustein
Maria Florez
Mary Jo Lamberti
Patricia (Trish) Davidson
Paul Beninger
Robert Franco
Ruby (Madison) Ford
Zachary (Zak) Smith
View:
5
10
25
50
Sort:
Oldest to Newest
Newest to Oldest
353 Results
Commentary
From the Editor In Chief: A Tribute to Dr. Louis C. Lasagna: 1923 - 2003
Drug Information Journal
Kenneth Kaitin
10/1/2003
Commentary
Beyond the Blockbuster
Pharmaceutical Executive
Kenneth Kaitin, Robert Franco
11/1/2002
Research Article
The Price of Innovation: New Estimates of Drug Development Costs
Journal of Health Economics
Joseph DiMasi
10/8/2002
Editorial
From the Editor-In-Chief: Regulatory Reform at a Crossroads
Drug Information Journal
Kenneth Kaitin
4/1/2002
Book Chapter
Uncertainty in Drug Development: Approval Success Rates for New Drugs
"Clinical Drug Trials and Tribulations, Revised and Expanded"
Joseph DiMasi
1/1/2002
Research Article
Returns on Research and Development for 1990s New Drug Introductions
PharmacoEconomics
Joseph DiMasi
1/1/2002
Commentary
New Drug Development in the United States from 1963 to 1999
Clinical Pharmacology & Therapeutics
Joseph DiMasi
5/2/2001
Research Article
Risk in New Drug Development: Approval Success Rates for Investigational Drugs
Clinical Pharmacology & Therapeutics
Joseph DiMasi
2/26/2001
Research Article
The ALPHA Project: Establishing Consensus and Prioritsation of Global Community Recommendations to Address Major Challenges of Lupus Diagnosis, Care, Treatment and Research
Lupus Science & Medicine
Kenneth Getz
2/9/2001
Research Article
Emerging Role of Pharmacoeconomics in the Research and Development Decision-Making Process
PharmacoEconomics
Joseph DiMasi
1/1/2001
Research Article
New Drug Innovation and Pharmaceutical Industry Structure: Trends in the Output of Pharmaceutical Firms
Therapeutic Innovation & Regulatory Science
Joseph DiMasi
12/31/2000
Report
Price Trends for Prescription Pharmaceuticals: 1995-1999
Department of Health and Human Services
Joseph DiMasi
8/8/2000
Research Article
Measuring the Pace of New Drug Development in the User Fee ERA
Therapeutic Innovation & Regulatory Science
Kenneth Kaitin, Joseph DiMasi
7/1/2000
Research Article
Breaking the Development Speed Barrier: Assessing Successful Practices of the Fastest Drug Development Companies
Therapeutic Innovation & Regulatory Science
Kenneth Getz
7/1/2000
Research Article
New Drug Approval Times and 'Therapeutic Potential' in Canada, Australia, Sweden and the United States During the Period 1992 to 1998
Canadian Journal of Clinical Pharmacology
Kenneth Kaitin
6/27/2000
Research Article
The New Drug Approvals of 1996, 1997, and 1998: Drug Development Trends in the User Fee Era
Therapeutic Innovation & Regulatory Science
Kenneth Kaitin
1/1/2000
Research Article
The European Agency for the Evaluation of Medicinal Products' Centralized Procedure for Product Approval: Current Status
Therapeutic Innovation & Regulatory Science
Kenneth Kaitin
10/1/1999
Research Article
Global Drug Development and International Harmonization: The Emergence of China as a World Pharmaceutical Player
Therapeutic Innovation & Regulatory Science
Kenneth Kaitin
10/1/1998
Research Article
Drug Review in Canada: A Comparison with Australia, Sweden, the United Kingdom, and the United States
Drug Information Journal
Kenneth Kaitin
1/1/1998
Research Article
Initiatives to Speed New Drug Development and Regulatory Review: The Impact of FDA-Sponsor Conferences
Drug Information Journal
Joseph DiMasi
12/30/1997
Research Article
The Prescription Drug User Fee Act of 1992 and the New Drug Development Process
American Journal of Therapeutics
Kenneth Kaitin
5/1/1997
Research Article
FDA Reform: Setting the Stage for Efforts to Reform the Agency
Therapeutic Innovation & Regulatory Science
Kenneth Kaitin
1/1/1997
Research Article
The New Drug Approvals of 1993, 1994, and 1995: Trends in Drug Development
American Journal of Therapeutics
Kenneth Kaitin
1/1/1997
Research Article
Factors Driving the Increased use of Outside Contractors in Drug Development
Clinical Research and Regulatory Affairs
Kenneth Getz
1/1/1997
Research Article
The Expanding Outside Clinical Services Contractor Marketplace
Clinical Research and Regulatory Affairs
Kenneth Getz
1/1/1997
Research Article
Recombinant Protein and Therapeutic Monoclonal Antibody Drug Development in the United States from 1980 to 1994
Clinical Pharmacology & Therapeutics
Joseph DiMasi
12/1/1996
Research Article
A New Look at Untied States Drug Development and Approval Times
American Journal of Therapeutics
Joseph DiMasi
9/1/1996
Research Article
An Analysis of Regulatory Review Times of Supplemental Indications for Already-Approved Drugs: 1989-1994
Drug Information Journal
Joseph DiMasi
4/1/1996
Research Article
The Prescription Drug User Fee Act of 1992. A 5-year Experiment for Industry and the FDA
Pharmacoeconomics
Kenneth Kaitin
2/1/1996
Research Article
Pharmaceutical Innovation in an Era of Reform
American Journal of Therapeutics
Kenneth Kaitin
9/1/1995
Research Article
Drug Safety Discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: A Regulatory Perspective
Clinical Pharmacology & Therapeutics
Kenneth Kaitin
7/1/1995
Research Article
Success Rates for New Drugs Entering Clinical Testing in the United States
Clinical Pharmacology & Therapeutics
Joseph DiMasi
7/1/1995
Research Article
A Drug Lag Update
Therapeutic Innovation & Regulatory Science
Kenneth Kaitin
4/1/1995
Research Article
Trends in Drug Development Costs, Times, and Risks
Drug Information Journal
Joseph DiMasi
4/1/1995
Research Article
Managing Research Centers as a Portfolio of Strategic Resources
Therapeutic Innovation & Regulatory Science
Kenneth Getz
4/1/1995
Research Article
Research and Development Costs for New Drugs by Therapeutic Category. A Study of the US Pharmaceutical Industry
PharmacoEconomics
Joseph DiMasi
2/1/1995
Research Article
R&D Costs, Innovative Output and Firm Size in the Pharmaceutical Industry
International Journal of the Economics of Business
Joseph DiMasi
1/1/1995
Research Article
New Drug Development in the United States from 1963 to 1992
Clinical Pharmacology & Therapeutics
Joseph DiMasi
6/1/1994
Research Article
Risks, Regulation, and Rewards in New Drug Development in the United States
Regulatory Toxicology and Pharmacology
Joseph DiMasi
4/1/1994
Research Article
The New Drug Approvals of 1990, 1991, and 1992: Trends in Drug Development
The Journal of Clinical Pharmacology
Kenneth Kaitin
2/1/1994
Research Article
The Role of the Research-Based Pharmaceutical Industry in Medical Progress in the United States
The Journal of Clinical Pharmacology
Kenneth Kaitin
5/1/1993
Research Article
Are Initiatives to Speed the New Drug Approval Process Working?
Therapeutic Innovation & Regulatory Science
Kenneth Kaitin
7/1/1992
Research Article
Pharmaceutical Regulation in the European Community: Barriers to Single Market Integration
"Journal of Health Politics, Policy and Law"
Kenneth Kaitin
1/1/1992
Research Article
Rising Research and Development Costs for New Drugs in a Cost Containment Environment
PharmacoEconomics
Joseph DiMasi
1/1/1992
Research Article
Implementation of the Orphan Drug Act: 1983-1991
Food and Drug Law Journal
Joseph DiMasi
1/1/1992
Research Article
Cost of Innovation in the Pharmaceutical Industry
Journal of Health Economics
Joseph DiMasi
7/1/1991
Research Article
New Indications for Already-Approved Drugs: An Analysis of Regulatory Review Times
The Journal of Clinical Pharmacology
Joseph DiMasi, Kenneth Kaitin
3/1/1991
Research Article
The New Drug Approvals of 1987, 1988, and 1989: Trends in Drug Development
The Journal of Clinical Pharmacology
Kenneth Kaitin
2/1/1991
Research Article
Case Studies of Expedited Review: AZT and L-Dopa
"Law, Medicine & Health Care"
Kenneth Kaitin
1/1/1991
Research Article
Impact of Policy Research on Drug Development Strategies
Therapeutic Innovation & Regulatory Science
Kenneth Kaitin
1/1/1990
Pagination
First page
« First
Previous page
‹ Previous
Page
1
Page
2
Page
3
Page
4
Page
5
Page
6
Current page
7
Page
8
Next page
Next ›
Last page
Last »